Zosano Announces Publication of Positive Data on Qtrypta’s™ Potential as an Acute Treatment for Patients with Difficult-to-Treat Migraines
31 janv. 2019 08h30 HE
|
Zosano Pharma Corporation
FREMONT, Calif., Jan. 31, 2019 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company, today announced the peer-reviewed...
Zosano Appoints Linda Grais M.D., J.D. to Board of Directors
16 janv. 2019 08h30 HE
|
Zosano Pharma Corporation
FREMONT, Calif., Jan. 16, 2019 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company, today announced the appointment of...
Zosano Receives Conditional FDA Acceptance of Proposed Brand Name Qtrypta™ for M207
12 déc. 2018 08h30 HE
|
Zosano Pharma Corporation
FREMONT, Calif., Dec. 12, 2018 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company, today announced that the U.S. Food...
Zosano Pharma Reports Third Quarter 2018 Financial Results and Operational Update
14 nov. 2018 16h05 HE
|
Zosano Pharma Corporation
Selected a contract manufacturer for commercial launch of M207Completed first required data set in long-term safety study of M207Appointed Greg Kitchener as Chief Financial Officer FREMONT,Calif.,...
Zosano Pharma to Host Conference Call on Third Quarter 2018 Financial Results and Provide Operational Update
07 nov. 2018 16h30 HE
|
Zosano Pharma Corporation
FREMONT, Calif., Nov. 07, 2018 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company, today announced that it will host...
Zosano Treats over 4,000 Migraines and Reaches an Important Goal in M207-ADAM Long-term Safety Study
23 oct. 2018 08h30 HE
|
Zosano Pharma Corporation
FREMONT, Calif., Oct. 23, 2018 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company, today announced that more than 150...
Zosano Pharma to Host Key Opinion Leader Meeting on New Treatments for Migraine and the Migraine Patients’ Perspective
18 oct. 2018 08h00 HE
|
Zosano Pharma Corporation
Live webcast of the event available for analysts and investors FREMONT, Calif., Oct. 18, 2018 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (Nasdaq: ZSAN) (“Zosano” or the “Company”), a...
Zosano Appoints New Chief Financial Officer
16 oct. 2018 08h30 HE
|
Zosano Pharma Corporation
Seasoned financial and operational executive further strengthens management team FREMONT, Calif., Oct. 16, 2018 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN) (“Zosano” or the...
Zosano Pharma Engages Contract Manufacturer as Part of the Commercialization Strategy for M207
03 oct. 2018 08h30 HE
|
Zosano Pharma Corporation
FREMONT, Calif., Oct. 03, 2018 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company developing and commercializing...
Zosano Pharma Enters Into Capital Equipment Lease Agreement With Trinity Capital Investment
26 sept. 2018 08h30 HE
|
Zosano Pharma Corporation
FREMONT, Calif., Sept. 26, 2018 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company developing and commercializing...